This federal Project Grant award of $915,000.00, effective July 1, 2024 through June 30, 2027, is provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research by the University of New Mexico Health Sciences Center (UNM HSC) to improve targeted ovarian cancer therapy using the novel Notch pathway inhibitor auranofin. UNM HSC, a major academic medical center, will leverage its expertise in cancer research to conduct this biomedical research initiative. The grant funding will enable UNM HSC to carry out innovative scientific studies ranging from basic laboratory work to advanced clinical trials, with the goal of developing more effective treatments for ovarian cancer.
Generated 1/28/25, 9:24 AM